

Faris Farassati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1681668/publications.pdf>

Version: 2024-02-01

31
papers

770
citations

516710

16
h-index

501196

28
g-index

31
all docs

31
docs citations

31
times ranked

1124
citing authors

#	ARTICLE	IF	CITATIONS
1	Cross-cultural validation of stool Based Colorectal cancer screening methods in the North West of Iran. <i>Annals of Medicine and Surgery</i> , 2022, 76, 103494.	1.1	1
2	<p>Targeting Cancer Stem Cells by Oncolytic Viruses and Nano-Mediated Delivery</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 9349-9350.	2.0	3
3	The APC gene rs41115 polymorphism is associated with survival in Iranian colorectal cancer patients. <i>Biomedical Research and Therapy</i> , 2020, 7, 3962-3970.	0.6	4
4	A Novel Oncolytic Herpes Capable of Cell-Specific Transcriptional Targeting of CD133± Cancer Cells Induces Significant Tumor Regression. <i>Stem Cells</i> , 2018, 36, 1154-1169.	3.2	17
5	Cancer stem cells, the ultimate targets in cancer therapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 183-184.	2.0	1
6	Association of clinicopathologic characteristics and outcomes with EZH2 expression in patients with breast cancer in East Azerbaijan, Iran. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 449-457.	2.0	5
7	Main Risk Factors Association with Proto-Oncogene Mutations in Colorectal Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 2183-2190.	1.2	8
8	A novel <i><sc>KRAS</sc></i> gene mutation report in sporadic colorectal cancer, from Northwest of Iran. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 338-341.	0.5	3
9	Ral signaling pathway in health and cancer. <i>Cancer Medicine</i> , 2017, 6, 2998-3013.	2.8	43
10	Ezh2, a novel target in detection and therapy of breast cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2685-2687.	2.0	9
11	Editorial announcing PubMed indexing of Oncolytic Virotherapy. <i>Oncolytic Virotherapy</i> , 2017, Volume 6, 19-20.	6.0	2
12	The role of KPNβ₁ in neuro-oncology. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2067-2068.	2.0	0
13	Association between proto-oncogene mutations and clinicopathologic characteristics and overall survival in colorectal cancer in East Azerbaijan, Iran. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7385-7395.	2.0	9
14	RalA is overactivated in medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 99-110.	2.9	15
15	Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44+ cancer stem cells. <i>Biomedicine and Pharmacotherapy</i> , 2015, 74, 243-251.	5.6	33
16	RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC). <i>Molecular Oncology</i> , 2014, 8, 1043-1053.	4.6	36
17	Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 77, 252-259.	2.0	35
18	Inhibition of Mesothelin as a Novel Strategy for Targeting Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e33214.	2.5	38

#	ARTICLE	IF	CITATIONS
19	Overactivation of Ras signaling pathway in CD133+MPNST cells. <i>Journal of Neuro-Oncology</i> , 2012, 108, 423-434.	2.9	18
20	Pro-Oncogenic Cell Signaling Machinery as a Target for Oncolytic Viruses. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1742-1749.	1.6	8
21	Utilizing Ras Signaling Pathway to Direct Selective Replication of Herpes Simplex Virus-1. <i>PLoS ONE</i> , 2009, 4, e6514.	2.5	33
22	Ral Overactivation in Malignant Peripheral Nerve Sheath Tumors. <i>Molecular and Cellular Biology</i> , 2009, 29, 3964-3974.	2.3	48
23	Transcription factors downstream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus. <i>Molecular Oncology</i> , 2009, 3, 464-468.	4.6	12
24	Protein kinase C- β inhibitor enzastaurin (LY317615.HCl) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. <i>Investigational New Drugs</i> , 2008, 26, 13-24.	2.6	28
25	Ras Signaling Influences Permissiveness of Malignant Peripheral Nerve Sheath Tumor Cells to Oncolytic Herpes. <i>American Journal of Pathology</i> , 2008, 173, 1861-1872.	3.8	31
26	Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3586-3597.	4.1	28
27	Ras Pathway Activation in Malignant Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2007, 2, 789-795.	1.1	31
28	Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids. <i>Oncogene</i> , 2005, 24, 2367-2374.	5.9	16
29	Ras Signalling Pathway: A Gateway for HSV-1 Infection. <i>Scientific World Journal</i> , The, 2003, 3, 533-535.	2.1	6
30	Oncolytic viruses and cancer therapy. <i>Cytokine and Growth Factor Reviews</i> , 2001, 12, 271-282.	7.2	34
31	Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. <i>Nature Cell Biology</i> , 2001, 3, 745-750.	10.3	215